Investigators out of the U.K. report that post-traumatic stress disorder (PTSD) patients who used cannabis-based medicinal products (CBMPs) seem to experience improved quality of life. They assessed the HRQoL of PTSD patients at one, three and six months. Canadian researchers reviewed studies looking at cannabis effects on PTSD symptoms, QoL and return to work. Of the 162 patients included in the review, just shy of 89 per cent of them were current/previous cannabis users. The most common adverse effects were insomnia and fatigue, reported by 20, or about 12.4 per cent, of those taking part in the study.
Investigators out of the U.K. report that post-traumatic stress disorder (PTSD) patients who used cannabis-based medicinal products (CBMPs) seem to experience improved quality of life.
Participants initiating CBMP therapy had associated improvements in health-related quality of life (HRQoL), researchers write in the study, published earlier this month in Expert Review of Neurotherapeutics.
“Adverse events analysis suggests acceptability and safety up to six months,” investigators point out, adding that findings “may inform randomized placebo-controlled trials, required to...
Read the full article @ The Growth Op